Lizet E. van der Kolk

Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers

Karoline Kuchenbaecker, John L. Hopper, Daniel R. Barnes et al. · JAMA · 2017 · 2.9K citations · Full text

Medicine, Genetics, Oncology +17

Complement activation plays a key role in the side‐effects of rituximab treatment

Lizet E. van der Kolk, A.J. Grillo-López, Joke W. Baars et al. · British Journal of Haematology · 2001 · 323 citations · Full text

Life Sciences, Hematology, Immunology +16

Mutational spectrum in a worldwide study of 29,700 families with<i>BRCA1</i>or<i>BRCA2</i>mutations

Timothy R. Rebbeck, Tara M. Friebel, Eitan Friedman et al. · Human Mutation · 2018 · 314 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Rituximab treatment results in impaired secondary humoral immune responsiveness

Lizet E. van der Kolk, Joke W. Baars, Martin H. Prins et al. · Blood · 2002 · 280 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +14

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

Esther H. Lips, Lennart Mulder, Anne M.M. Oonk et al. · British Journal of Cancer · 2013 · 241 citations · Full text

Medicine, Genetics, Oncology +16